
VO-Ohpic trihydrate
CAS No. 476310-60-8
VO-Ohpic trihydrate ( VO-Ohpic | VO Ohpic )
产品货号. M14588 CAS No. 476310-60-8
VO-Ohpic 三水合物 (VO-Ohpic) 是一种有效的、选择性的、可逆的 PTEN 抑制剂,体外 IC50 为 35 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥421 | 有现货 |
![]() ![]() |
10MG | ¥640 | 有现货 |
![]() ![]() |
25MG | ¥1191 | 有现货 |
![]() ![]() |
50MG | ¥2130 | 有现货 |
![]() ![]() |
100MG | ¥3070 | 有现货 |
![]() ![]() |
200MG | ¥4577 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称VO-Ohpic trihydrate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述VO-Ohpic 三水合物 (VO-Ohpic) 是一种有效的、选择性的、可逆的 PTEN 抑制剂,体外 IC50 为 35 nM。
-
产品描述VO-Ohpic trihydrate (VO-Ohpic) is a potent, selective and reversible PTEN inhibitor with IC50 of 35 nM in vitro; specifically inhibits PTEN’s cellular enzymatic activity, which in turn activates downstream targets such as Akt and FoxO3a, inhibits cell viability, cell proliferation and colony formation, and induces senescence-associated β-galactosidase activity in Hep3B cells (low PTEN expression); increases cellular PIP3 levels, phosphorylation of Akt, and glucose uptake in adipocytes at nanomolar concentrations; decreases left ventricular systolic pressure and heart rate before ischemia in mice.
-
体外实验VO-OHpic with two OHpic ligands and an oxo ligand is a sterically demanding molecule, and one will therefore expect that binds substrate will affect the subsequent binding of the inhibitor due to steric hindrance. VO-OHpic significantly inhibits PTEN activity in low nanomolar concentrations (IC50, 46±10 nM), which is in agreement with the previously determined potency (IC50, 35±2 nM) in a PIP3-based assay. The inhibition constants Kic and Kiu are determined to be 27±6 and 45±11 nM, respectively. VO-OHpic is an encouragingly specific and potent PTEN inhibitor. VO-OHpic is the most potent inhibitor (IC50=35 nM) of the PTEN lipid phosphatase activity.
-
体内实验PTEN is inhibited in mice by intra-peritoneal injection of VO-OHpic (10 μg/kg) 30 min before ischemia and then exposed them to 30 min of ischemia and 120 min of reperfusion. At the end of the experiment, myocardial infarct size is measured by triphenyltetrazolium chloride (TTC). Myocardial infarct size is significantly decreased in VO-treated mice (25±6 vs. 56±5 %, n=7, P<0.01). There is no difference in the area at risk between these two groups (46±3 vs. 57±3 %, n=7, P>0.05).
-
同义词VO-Ohpic | VO Ohpic
-
通路Others
-
靶点PTEN
-
受体PTEN
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number476310-60-8
-
分子量415.2032
-
分子式C12H16N2O11V+
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO; H2O: < 0.1 mg/mL
-
SMILESO=[V](OC(C1=NC=CC=C1O)=O)(O)OC(C2=NC=CC=C2O)=O.O.O.O
-
化学全称Vanadate(1-), aqua(3-hydroxy-2-pyridinecarboxylato-κN1,κO2)[3-(hydroxy-κO)-2-pyridinecarboxylato(2-)-κO2]oxo-, hydrogen, trihydrate, (OC-6-45)- (9CI)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Rosivatz E, et al. ACS Chem Biol. 2006 Dec 15;1(12):780-90.
2. Zu L, et al. Eur J Pharmacol. 2011 Jan 10;650(1):298-302.
3. Mak LH, et al. J Chem Biol. 2010 Oct;3(4):157-63.
4. Augello G, et al. Cell Cycle. 2016;15(4):573-83.